Navigation Links
Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results
Date:10/14/2008

SOMERSET, N.J., Oct. 14 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported its financial results for the fourth quarter and fiscal year ended July 31, 2008.

The company recorded a net loss of approximately $2.9 million, or $0.06 per basic and diluted common share, for the fourth fiscal quarter ended July 31, compared to a net loss of approximately $2.4 million, or $0.05 per basic and diluted common share, for the fourth quarter of fiscal 2007. Research and development expenses increased by approximately $0.9 million during the fourth quarter of fiscal 2008 as compared to the same quarter a year ago primarily due to expenses incurred related to the company's preparations for the completion of its ONCONASE(R) rolling New Drug Application (NDA) submission. Decreased general and administrative expenses of approximately $0.5 million for the fourth quarter of fiscal 2008 were primarily the result of reduced stock based compensation expenses.

Net loss for the fiscal year ended July 31, 2008 of approximately $12.3 million, or $0.26 per basic and diluted common share, represents an increase of approximately $3.5 million, compared to the $8.8 million net loss, or $0.19 per basic and diluted common share, for fiscal 2007.

Cash and Liquidity

As of July 31, 2008, the company had cash and cash equivalents of approximately $4.7 million, a decrease of approximately $3.1 million, compared to cash and cash equivalents of approximately $7.8 million on April 30, 2008. The company has received notification that it continues to qualify for the sale of its state tax loss carryforwards in New Jersey and is awaiting additional information on the proceeds it can expect to receive from this sale in late 2008
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Paper in Cell Cycle Reports Alfacells ONCONASE(R) Targets siRNA
2. Alfacell Hires Advisors to Advance Strategic Alternatives
3. Alfacell Receives NASDAQ Delisting Letter
4. Alfacell Receives NASDAQ Non-Compliance Notification
5. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
6. Alfacell Announces Retirement of Chief Executive Officer
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
9. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
10. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
11. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  An entire month is dedicated ... neuropathies – Charcot-Marie-Tooth disease (CMT) – a debilitating neuromuscular ... extreme muscle atrophy, weakness, and foot and hand deformities. ... millions worldwide. CMT is a progressive disease, and over ... requiring mobility devices such as leg braces, wheelchairs and ...
(Date:9/19/2014)... CORAL SPRINGS, Florida , September 19, 2014 /PRNewswire/ ... biotech companies release latest developments, patents and results of ... (OTC: GNSZ), Eli Lilly and Company (NYSE: ... ), Celgene Corporation (NASDAQ: CELG ) and ... (OTCQB: GNSZ), a leader in developing prodrug therapeutics for ...
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
Breaking Biology Technology:September is Charcot-Marie-Tooth (CMT) Awareness Month - Scheduled events, activities and important partnerships announced throughout the month! 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2
... After receiving FDA clearance for two new brain imaging ... to market its products to healthcare providers. , ,Approval ... for Devices and Radiologic Health in June allowed ... products to its line of brain mapping solutions based ...
... Healthcare has received permission to continue trading company stock ... listing standards. , ,Merge, a developer of medical imaging and ... will allow it to continue listing its common stock subject ... 29, 2006. The company was unable to comply with filing ...
... is a world-class company and object of emulation for many. ... true conglomerate, but one that is more than an investment ... from aircraft engines and massive power-generating turbines to financial services ... GE is knowledge intensive in all its businesses and global ...
Cached Biology Technology:Kyron wins FDA approval for brain imaging technology 2Growth through the eyes of GE's Immelt 2Growth through the eyes of GE's Immelt 3Growth through the eyes of GE's Immelt 4Growth through the eyes of GE's Immelt 5
(Date:9/18/2014)... its newborn screening program into a model other states can ... first-ever Newborn Screening Quality Award from the March of Dimes. ... Arizona,s Department of Health Services director, with the award at ... of full transparency for the length of time it takes ... for analysis, and set a target of having 95 percent ...
(Date:9/18/2014)... several disciplines will be celebrated tonight at the third ... improving the health of premature infants and in paving ... researchers, whose work was supported by the National Science ... Atomic Energy Commission, will be honored at a ceremony ... bipartisan group of Members of Congress will be on ...
(Date:9/18/2014)... 18, 2014 Elsevier, a world-leading provider of ... and the Australasian Research Management Society (ARMS), recognized ... at the 5th Scopus Young Researcher of the ... today at the National Convention Centre and in ... attended by guests representing Australia,s and New Zealand,s ...
Breaking Biology News(10 mins):March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2
... Jerrold Meyer and colleagues at the University of Massachusetts ... as an important new biomarker for stress in wild ... demonstrated in the current issue of the Journal ... lab manager Kendra Rosenberg and neuroscience and behavior graduate ...
... 2014) Researchers from Massachusetts Eye and Ear, ... Massachusetts General Hospital have demonstrated, for the first ... of vestibular schwannomas (also known as acoustic neuromas), ... hearing loss and tinnitus. Motivated by ...
... and why now? , Islands are renowned for their ... biogeography, and ecology. As a result of the devastating ... and island conservation has become a vital international concern. ... islands at an unprecedented pace, and now is an ...
Cached Biology News:Biomarker for stress hormones in polar bears, wildlife affected by global climate change 2Aspirin intake may stop growth of vestibular schwannomas/acoustic neuromas 2Island Biology 2014: An International Conference on Island Evolution, Ecology, and Conservation 2
... Immunogen: KLH-conjugated, synthetic peptide ... which [ Ac K] corresponds to acetyl ... Accession Number: NM_003493 ... Quality Assurance: Routinely ...
synaptotagmin XIV-like [Source:RefSeq_peptide;Acc:NP_114120] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Naked1 Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
Biology Products: